Vaxxitek HVT+IBD


Infectious bursal disease and Marek's disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 17/01/2020

Authorisation details

Product details
Vaxxitek HVT+IBD
Agency product number
Active substance
Recombinant turkey herpesvirus, strain vhvt013-69, live
International non-proprietary name (INN) or common name
Infectious bursal disease and Marek's disease vaccine (live recombinant)
  • Embryonated eggs
  • Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

19/12/2019 Vaxxitek HVT+IBD - EMEA/V/C/000065 - T/0028


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Domestic fowl

  • Immunologicals

Therapeutic indication

For active immunisation of chickens:

  • To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
  • To reduce mortality, clinical signs and lesions of Marek's disease.

Assessment history

How useful was this page?

Add your rating
1 rating